The potential of exosomes in immunotherapy of cancer

Nathalie Chaput; Julien Taïeb; Noël Schartz; Caroline Flament; Sophie Novault; Fabrice André; Laurence Zitvogel

doi:10.1016/j.bcmd.2005.05.009

The potential of exosomes in immunotherapy of cancer

Nathalie Chaput, Julien Taïeb, Noël Schartz, Caroline Flament, Sophie Novault, Fabrice André, Laurence Zitvogel

Research output: Contribution to journal › Article › peer-review

40 Citations (Scopus)

Abstract

Dendritic-cell-derived exosomes (DEX) secreted after dendritic cell loading with tumor peptides were found to mediate tumor rejection in mice. This observation prompted us to demonstrate that MHC class I/peptide complexes harbored onto exosomal membranes were capable of priming cytotoxic T cells and to mediate rejection of tumors expressing the relevant antigens. Moreover, DEX also promote NK cell activation in immunocompetent mice and NK cell-dependent antitumor effects. The first Phase I trial using DEX to immunize melanoma patients revealed the feasibility of DEX production in stage IV melanoma, their safety in long-term follow up and their bioactivity in vivo.

Original language	English
Pages (from-to)	111-115
Number of pages	5
Journal	Blood Cells, Molecules, and Diseases
Volume	35
Issue number	2
DOIs	https://doi.org/10.1016/j.bcmd.2005.05.009
Publication status	Published - 1 Sept 2005

Keywords

Cross presentation
Exosomes
Immunotherapy
MHC complexes
Tumor

Access to Document

10.1016/j.bcmd.2005.05.009

Cite this

@article{6fe3f021cf8e4bd4a257cf6af77f0f37,

title = "The potential of exosomes in immunotherapy of cancer",

abstract = "Dendritic-cell-derived exosomes (DEX) secreted after dendritic cell loading with tumor peptides were found to mediate tumor rejection in mice. This observation prompted us to demonstrate that MHC class I/peptide complexes harbored onto exosomal membranes were capable of priming cytotoxic T cells and to mediate rejection of tumors expressing the relevant antigens. Moreover, DEX also promote NK cell activation in immunocompetent mice and NK cell-dependent antitumor effects. The first Phase I trial using DEX to immunize melanoma patients revealed the feasibility of DEX production in stage IV melanoma, their safety in long-term follow up and their bioactivity in vivo.",

keywords = "Cross presentation, Exosomes, Immunotherapy, MHC complexes, Tumor",

author = "Nathalie Chaput and Julien Ta{\"i}eb and No{\"e}l Schartz and Caroline Flament and Sophie Novault and Fabrice Andr{\'e} and Laurence Zitvogel",

note = "Funding Information: This work has been funded by Anosys Inc., INSERM, Ligue Labellis{\'e}e Contre le Cancer and ARC. The manuscript is based on a presentation at a Focused Workshop on “Exosomes: Biological Significance” Montr{\'e}al, Qu{\'e}bec, May 20–21, 2005, sponsored by The Leukemia and Lymphoma Society.",

year = "2005",

month = sep,

day = "1",

doi = "10.1016/j.bcmd.2005.05.009",

language = "English",

volume = "35",

pages = "111--115",

journal = "Blood Cells, Molecules, and Diseases",

issn = "1079-9796",

number = "2",

}

TY - JOUR

T1 - The potential of exosomes in immunotherapy of cancer

AU - Chaput, Nathalie

AU - Taïeb, Julien

AU - Schartz, Noël

AU - Flament, Caroline

AU - Novault, Sophie

AU - André, Fabrice

AU - Zitvogel, Laurence

N1 - Funding Information: This work has been funded by Anosys Inc., INSERM, Ligue Labellisée Contre le Cancer and ARC. The manuscript is based on a presentation at a Focused Workshop on “Exosomes: Biological Significance” Montréal, Québec, May 20–21, 2005, sponsored by The Leukemia and Lymphoma Society.

PY - 2005/9/1

Y1 - 2005/9/1

N2 - Dendritic-cell-derived exosomes (DEX) secreted after dendritic cell loading with tumor peptides were found to mediate tumor rejection in mice. This observation prompted us to demonstrate that MHC class I/peptide complexes harbored onto exosomal membranes were capable of priming cytotoxic T cells and to mediate rejection of tumors expressing the relevant antigens. Moreover, DEX also promote NK cell activation in immunocompetent mice and NK cell-dependent antitumor effects. The first Phase I trial using DEX to immunize melanoma patients revealed the feasibility of DEX production in stage IV melanoma, their safety in long-term follow up and their bioactivity in vivo.

AB - Dendritic-cell-derived exosomes (DEX) secreted after dendritic cell loading with tumor peptides were found to mediate tumor rejection in mice. This observation prompted us to demonstrate that MHC class I/peptide complexes harbored onto exosomal membranes were capable of priming cytotoxic T cells and to mediate rejection of tumors expressing the relevant antigens. Moreover, DEX also promote NK cell activation in immunocompetent mice and NK cell-dependent antitumor effects. The first Phase I trial using DEX to immunize melanoma patients revealed the feasibility of DEX production in stage IV melanoma, their safety in long-term follow up and their bioactivity in vivo.

KW - Cross presentation

KW - Exosomes

KW - Immunotherapy

KW - MHC complexes

KW - Tumor

UR - http://www.scopus.com/inward/record.url?scp=24644466386&partnerID=8YFLogxK

U2 - 10.1016/j.bcmd.2005.05.009

DO - 10.1016/j.bcmd.2005.05.009

M3 - Article

C2 - 16027014

AN - SCOPUS:24644466386

SN - 1079-9796

VL - 35

SP - 111

EP - 115

JO - Blood Cells, Molecules, and Diseases

JF - Blood Cells, Molecules, and Diseases

IS - 2

ER -

The potential of exosomes in immunotherapy of cancer

Abstract

Keywords

Access to Document

Other files and links

Cite this